Treatment options for PsA, following non-steroidal anti-inflammatory drugs (NSAIDs), include conventional synthetic disease modifying anti-rheumatic drugs (csDMARDS), particularly methotrexate (MTX). The present study was performed to determine the non-adherence and discontinuation rates of different methotrexate (MTX) formulations in psoriatic arthritis (PsA).

Non-adherence and discontinuation rate for oral and parenteral methotrexate: A retrospective-cohort study in 8,952 patients with psoriatic arthritis

De Santis, Maria;Ceribelli, Angela;Selmi, Carlo
2021-01-01

Abstract

Treatment options for PsA, following non-steroidal anti-inflammatory drugs (NSAIDs), include conventional synthetic disease modifying anti-rheumatic drugs (csDMARDS), particularly methotrexate (MTX). The present study was performed to determine the non-adherence and discontinuation rates of different methotrexate (MTX) formulations in psoriatic arthritis (PsA).
2021
Adherence
HCQ, hydroxychloroquine
HR, Hazard ratio
IQR, inter-quartile range
LEF, leflunomide
MTX, methotrexate
Methotrexate
NSAIDs, non-steroidal anti-inflammatory drugs
OGC, oral glucocorticoids
Oral
Parenteral
PsA, psoriatic arthritis
PsO, psoriasis
Psoriatic arthritis
Retention rate
SSZ, sulfasalazine
TNF, tumor necrosis factor alpha
list: csDMARDs, conventional synthetic disease modifying anti-rheumatic drugs
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/68463
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact